Loading
GOLSEEK-1 is a recruiting phase 3 that tests whether adding golcadomide, an oral cereblon-modulating degrader, to R-CHOP raises cure rates in untreated high-risk large B-cell lymphoma. It builds on high complete response rates in phase 1b, and readout is expected in 2027 to 2028.
GOLSEEK-1, trial NCT06356129 sponsored by Bristol Myers Squibb, tests whether adding golcadomide, a potent oral cereblon-modulating degrader, to R-CHOP raises cure rates in untreated high-risk large B-cell lymphoma with IPI 3 to 5. It builds on phase 1b data with high complete response rates, and readout is expected in 2027 to 2028. OnCo links it to lymphoma and golcadomide. It is recruiting with no results, and whether an oral degrader can do in the frontline what lenalidomide failed to do in earlier trials is the question it will answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Golcadomide, Diffuse large B-cell lymphoma.
Shares Golcadomide, PROTACs & molecular glues (targeted protein degradation).
Shares Golcadomide, PROTACs & molecular glues (targeted protein degradation).
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/